How low is the α/β ratio for prostate cancer? In regard to Wang et al. [2] (multiple letter)

International Journal of Radiation Oncology Biology Physics

Volumn 57, Issue 2, 2003, Pages 593-595

  Fowler, Jack F ^a   Ritter, Mark A ^a   Fenwick, John D ^a   Chappell, Rick J ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA RADIATION; BETA RADIATION; CANCER RADIOTHERAPY; CELL PROLIFERATION; DOSE CALCULATION; HUMAN; LETTER; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; RADIATION DOSE; TREATMENT OUTCOME;

EID: 0042383102     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(03)00364-X     Document Type: Letter

References (23)

1. Wang J.Z., Guerrero M., Allen Li X. How low is the α/β ratio for prostate cancer? Int J Radiat Oncol Biol Phys. 55:(1):2003;194-203.
2. Fowler J., Chappell R., Ritter M. Is α/β for prostate cancer really low? Int J Radiat Oncol Biol Phys. 50:2001;1021-1031.
3. Brenner D.J., Hall E.J. Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys. 43:1999;1095-1101.
4. Brenner D.J., Martinez A.A., Edmundson G.K., et al. Direct evidence that prostate tumors show high sensitivity to fractionation (low α/β ratio) comparable to late-responding normal tissue. Int J Radiat Oncol Biol Phys. 52:2002;6-13.
5. Fowler JF, Ritter MA, Chappell RJ, Brenner DJ. What hypofractionated protocols should be tested for prostate cancer? Int J Radiat Oncol Biol Phys 2003;56:1093-1104.
6. Ritter MA, Chappell RJ, Fowler JF. Optimizing the design of hypofractionation trials in prostate cancer. Int J Radiat Oncol Biol Phys 2003. In preparation/submitted.
7. Catton CN, Chung P, Haycocks T, et al. Hypofractionated intensity modulated radiation therapy for prostate cancer [Abstract 1051]. Int J Radiat Oncol Biol Phys 2002;54(2S):188.
8. Roberts S.A., Hendry J.H. The delay before onset of accelerated tumor cell repopulation during radiotherapy A direct-maximum likelihood analysis of a collection of world-wide tumor-control data . Radiother Oncol. 29:1993;69-74.
9. Brenner D.J. Accelerated repopulation during radiotherapy; quantitative evidence for delayed onset. Radiat Oncol Invest. 1:1993;167-172.
10. Begg A.C., Hofland I., Van Glabbeke M., et al. Predictive value of potential doubling time for radiotherapy of head and neck tumor patients. Semin Radiat Oncol. 1:1992;22-25.
11. Zackrisson B., Gustafsson H., Stenling R., et al. Predictive value of potential doubling time in head and neck cancer patients treated by conventional radiotherapy. Int J Radiat Oncol Biol Phys. 38:(4):1997;677-683.
12. Fowler J.F. Rapid repopulation in radiotherapy A debate on mechanism . Radiother Oncol. 22:1991;156-158.
13. Haustermans K., Fowler J.F. A comment on proliferation rates in human prostate cancer. Int J Radiat Oncol Biol Phys. 48:(1):2000;303.
14. Pollack A., Zagars G.K., Kavadi V.S. Prostate specific antigen doubling times and disease relapse after radiotherapy for prostate cancer. Cancer. 74:1994;670-678.
15. Kampinga H.H., Hiemstrat Y.S., Konings A.W.T., et al. Correlation between slowly repairable double-strand breaks and thermal radiosensitization in the human HeLa S3 cell line. Int J Radiat Biol. 72:1977;293-301.
16. Thames H.D., Bentzen S.M., Turresson I., et al. Fractionation parameters for human tissues and tumors. Int J Radiat Biol. 56:(5):1989;701-710.
17. Steel G.G. Basic clinical radiobiology. 2nd ed. 1997;Edward Arnold, London (UK). p. 116.
18. Bentzen S.M., Ruifrok A.C.C., Thames H.D. Repair capacity and kinetics for human mucosal and epithelial tumors in the head and neck Clinical data on the effect of changing the time interval between multiple fractions per day in radiotherapy . Radiother Oncol. 38:1996;89-101.
19. Bentzen S.M., Saunders M.I., Dische S. Repair half-times estimated from observations of treatment-related morbidity after CHART or conventional radiotherapy in head and cancer. Radiother Oncol. 53:1999;219-226.
20. Dale RG, Jones B. Is the α/β for prostate tumors really low? In regard to [RBE in] Fowler et al. [Ref 2 above] (letter). Int J Radiat Oncol Biol Phys 2002;52:1427-1428.
21. Chappell R., Fowler J.F., Ritter M.A. In response to Drs. Dale and Jones. (letter) Int J Radiat Oncol Biol Phys. 52:2002;1428.
22. Zaider M., Minerbo G.N. Tumor control probability A formulation applicable to any temporal protocol of dose delivery . Phys Med Biol. 45:2000;279-293.
23. Levegrün S., Jackson A., Zelefsky M.J., et al. Fitting tumor control probability models to biopsy outcome after three-dimensional conformal radiation therapy of prostate cancer Pitfalls in deduction of radiobiologic parameters for tumors from clinical data . Int J Radiat Oncol Biol Phys. 51:2001;1064-1080.